BRPI0017596B8 - método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente - Google Patents
método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um pacienteInfo
- Publication number
- BRPI0017596B8 BRPI0017596B8 BRPI0017596A BRPI0017596A BRPI0017596B8 BR PI0017596 B8 BRPI0017596 B8 BR PI0017596B8 BR PI0017596 A BRPI0017596 A BR PI0017596A BR PI0017596 A BRPI0017596 A BR PI0017596A BR PI0017596 B8 BRPI0017596 B8 BR PI0017596B8
- Authority
- BR
- Brazil
- Prior art keywords
- radiolabeling
- antibody
- chelator
- antibody conjugated
- administration
- Prior art date
Links
- 238000000163 radioactive labelling Methods 0.000 title abstract 5
- 239000002738 chelating agent Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000000159 protein binding assay Methods 0.000 abstract 2
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 208000019420 lymphoid neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Packages (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/259,337 US20020102208A1 (en) | 1999-03-01 | 1999-03-01 | Radiolabeling kit and binding assay |
| BRPI0008719 BRPI0008719B8 (pt) | 1999-03-01 | 2000-02-29 | Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo |
| PCT/US2000/005061 WO2000052473A2 (en) | 1999-03-01 | 2000-02-29 | Radiolabeling kit and binding assay |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0017596A2 BRPI0017596A2 (pt) | 2011-09-27 |
| BRPI0017596B1 BRPI0017596B1 (pt) | 2015-09-01 |
| BRPI0017596B8 true BRPI0017596B8 (pt) | 2023-04-25 |
Family
ID=22984524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0017596A BRPI0017596B8 (pt) | 1999-03-01 | 2000-02-29 | método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente |
| BRPI0008719 BRPI0008719B8 (pt) | 1999-03-01 | 2000-02-29 | Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0008719 BRPI0008719B8 (pt) | 1999-03-01 | 2000-02-29 | Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo |
Country Status (35)
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US20020102208A1 (en) * | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US6207858B1 (en) * | 1999-03-03 | 2001-03-27 | Idec Pharmaceuticals Corporation | Regioselective synthesis of DTPA derivatives |
| EP1918305A1 (en) | 1999-08-11 | 2008-05-07 | Biogen Idec Inc. | New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy |
| WO2002028481A2 (en) | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| EP1383800A4 (en) * | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| CA2447695C (en) | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| IL159422A0 (en) | 2001-09-20 | 2004-06-01 | Cornell Res Foundation Inc | Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen |
| ES2314272T3 (es) | 2003-01-10 | 2009-03-16 | Millennium Pharmaceuticals, Inc. | Metodos para el diagnostico y el tratamiento del cancer. |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| DK1638989T3 (da) * | 2003-06-25 | 2008-11-17 | Peregrine Pharmaceuticals Inc | Fremgangsmåde og apparat til kontinuerlig radiomærkning af proteiner i stor målestok |
| AU2004287879C1 (en) | 2003-11-04 | 2011-05-26 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-CD40 monoclonal antibodies and methods for their use |
| US20070098718A1 (en) | 2003-11-04 | 2007-05-03 | Chiron | Methods of therapy for b cell-related cancers |
| DK1680141T3 (da) | 2003-11-04 | 2010-11-01 | Novartis Vaccines & Diagnostic | Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet |
| PT1684805E (pt) | 2003-11-04 | 2010-10-26 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo |
| PL1682177T3 (pl) | 2003-11-04 | 2011-03-31 | Novartis Vaccines & Diagnostics Inc | Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej |
| EP2312315A1 (en) | 2005-05-18 | 2011-04-20 | Novartis AG | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| US20080214933A1 (en) * | 2005-08-25 | 2008-09-04 | Koninklijke Philips Electronics, N.V. | Image-Based Planning Methods and Apparatus for Targeted Therapy |
| CN104090095B (zh) * | 2005-11-23 | 2016-06-01 | 文塔纳医疗系统公司 | 分子缀合物 |
| SMP200800064B (it) | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| HUE030850T2 (en) | 2006-06-16 | 2017-06-28 | Univ Pennsylvania | Prostaglandin D2 receptor antagonists for the treatment of hair loss |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| WO2008055997A1 (en) * | 2006-11-10 | 2008-05-15 | Alphaptose Gmbh | Use of tri-substituted glycerol compounds for the treatment of radiation injuries |
| CZ300074B6 (cs) * | 2006-12-20 | 2009-01-21 | Azacycles S. R. O. | Inteligentní trífunkcní makrokonjugáty a farmaceutický nebo diagnostický prostredek s jejich obsahem |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| GEP20125693B (en) | 2007-01-09 | 2012-11-26 | Biogen Idec Inc | Sp35 antibodies and usage thereof |
| WO2009080541A1 (en) * | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Antibody formulation |
| EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
| AU2008359583B2 (en) | 2008-07-16 | 2012-04-05 | Institute For Research In Biomedicine | Human cytomegalovirus neutralising antibodies and use thereof |
| PE20141398A1 (es) | 2008-07-16 | 2014-10-18 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| CA2731686C (en) | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| WO2010043977A2 (en) | 2008-10-13 | 2010-04-22 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| CN102341411A (zh) | 2008-12-31 | 2012-02-01 | 比奥根艾迪克Ma公司 | 抗-淋巴细胞毒素抗体 |
| US20110212106A1 (en) | 2010-01-20 | 2011-09-01 | Institute For Research In Bioscience | Hiv-1 neutralizing antibodies and uses thereof |
| EP3117709B1 (en) | 2010-03-12 | 2018-08-01 | Genzyme Corporation | Combination therapy for treating breast cancer |
| PT2591006T (pt) | 2010-07-09 | 2019-07-29 | Bioverativ Therapeutics Inc | Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas |
| PT2601214T (pt) | 2010-08-06 | 2017-12-20 | Genzyme Corp | Composições de antagonistas de vegf e utilizações destes |
| CN103237902A (zh) * | 2010-08-13 | 2013-08-07 | Rdm企业股份有限公司 | 减少糖的颜色的方法和组合物 |
| PT3045183T (pt) | 2011-03-11 | 2018-11-02 | Genzyme Corp | Apelina peguilada e suas utilizações |
| HUE044089T2 (hu) | 2011-07-18 | 2019-09-30 | Inst Res Biomedicine | Neutralizáló anti-influenza A antitestek és alkalmazásaik |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| KR102149069B1 (ko) | 2012-03-20 | 2020-08-28 | 후맙스 바이오메드 에스에이 | Rsv, mpv 및 pvm를 중화하는 항체 및 이의 용도 |
| WO2013148296A1 (en) | 2012-03-28 | 2013-10-03 | Sanofi | Antibodies to bradykinin b1 receptor ligands |
| WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| RU2522203C2 (ru) * | 2012-06-26 | 2014-07-10 | Василий Александрович Ишутин | Способ контроля стерилизации материалов и изделий |
| EP2872894B1 (en) * | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| EP2916872B1 (en) | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| US9580511B2 (en) | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| WO2014165216A1 (en) | 2013-03-12 | 2014-10-09 | The Trustees Of The University Of Pennsylvania | Diagnosing and treating cancer |
| US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
| WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| KR20160042871A (ko) | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
| RU2558929C2 (ru) * | 2013-08-08 | 2015-08-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" (НИИ Кардиологии) | СПОСОБ ОПРЕДЕЛЕНИЯ СВЯЗЫВАНИЯ РАДИОФАРМПРЕПАРАТА НА ОСНОВЕ ЦИПРОФЛОКСАЦИНА, МЕЧЕННОГО 99mTc C БАКТЕРИЯМИ |
| BR112016002753A2 (pt) | 2013-08-13 | 2017-11-21 | Sanofi Sa | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos |
| US11052177B2 (en) | 2013-09-06 | 2021-07-06 | The Trustees Of The University Of Pennsylvania | Antimicrobial polymer layers |
| SG11201602522VA (en) | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| JP6156962B2 (ja) | 2014-02-27 | 2017-07-05 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | エキソソームを単離するための方法および組成物 |
| HUE061339T2 (hu) | 2014-03-19 | 2023-06-28 | Genzyme Corp | Targetáló csoportok helyspecifikus glikotechnikai átalakítása |
| KR102731863B1 (ko) | 2014-03-27 | 2024-11-19 | 버드 락 바이오, 인크. | 인간 카나비노이드 1(cb1) 수용체 결합 항체 |
| WO2016011035A2 (en) | 2014-07-15 | 2016-01-21 | Medlmmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| US12214038B2 (en) | 2014-07-22 | 2025-02-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for cancer immunotherapy |
| US20170296650A1 (en) | 2014-10-08 | 2017-10-19 | Novartis Ag | Combination of human cytomegalovirus neutralizing antibodies |
| PL3204425T3 (pl) | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glikomodyfikowane koniugaty przeciwciał z lekami |
| WO2016075546A2 (en) | 2014-11-14 | 2016-05-19 | Antonio Lanzavecchia | Antibodies that neutralize ebola virus and uses thereof |
| EP3831404B1 (en) | 2014-11-18 | 2026-01-28 | Humabs Biomed S.A. | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof |
| MX389708B (es) | 2015-06-01 | 2025-03-20 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| ES2947824T3 (es) | 2015-07-30 | 2023-08-21 | Univ Pennsylvania | Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2 |
| US10278438B2 (en) | 2015-08-31 | 2019-05-07 | Grabbies Media, Llc | Consumer usable device with redeemable member |
| EP3349791A1 (en) | 2015-09-15 | 2018-07-25 | Board of Regents, The University of Texas System | T-cell receptor (tcr)-binding antibodies and uses thereof |
| CA3000167A1 (en) | 2015-09-30 | 2017-04-06 | Bird Rock Bio, Inc. | Antibodies that bind human cannabinoid 1 (cb1) receptor |
| WO2017059878A1 (en) | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| JP2019502715A (ja) | 2016-01-13 | 2019-01-31 | メディミューン,エルエルシー | A型インフルエンザを治療する方法 |
| WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| EP3612562A2 (en) | 2017-04-19 | 2020-02-26 | Institute for Research in Biomedicine | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to |
| JP7246320B2 (ja) | 2017-05-05 | 2023-03-27 | バクシネックス インコーポレーティッド | ヒト抗セマフォリン4d抗体 |
| KR20200038481A (ko) | 2017-07-19 | 2020-04-13 | 호프만 테크놀로지스, 인크. | 스트레스-관련 장애를 치료하기 위한 조성물 |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| CN109550061A (zh) * | 2017-09-26 | 2019-04-02 | 南京江原安迪科正电子研究发展有限公司 | 一种用于放射性核素标记抗体的试剂盒及应用 |
| RU2700584C1 (ru) * | 2018-12-13 | 2019-09-18 | Общество С Ограниченной Ответственностью "Апто-Фарм" | Способ оценки сродства олигонуклеотида |
| SI3898668T1 (sl) | 2018-12-19 | 2024-02-29 | Humabs Biomed Sa | Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe |
| JP7575401B2 (ja) | 2019-04-03 | 2024-10-29 | ジェンザイム・コーポレーション | 断片化が低減した抗アルファベータtcr結合ポリペプチド |
| US20220380441A1 (en) | 2019-08-29 | 2022-12-01 | Vir Biotechnology, Inc. | Antibody compositions and methods for treating hepatitis b virus infection |
| AU2021225962A1 (en) | 2020-02-28 | 2022-10-20 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
| EP4164745A1 (en) | 2020-06-11 | 2023-04-19 | Vaccinex, Inc. | Use of cxcl13 binding molecules to promote peripheral nerve regeneration |
| JP2024504167A (ja) | 2021-01-26 | 2024-01-30 | ヴィア・バイオテクノロジー・インコーポレイテッド | B型肝炎ウイルス感染を処置するための抗体組成物および方法 |
| TW202430561A (zh) | 2022-09-30 | 2024-08-01 | 法商賽諾菲公司 | 抗cd28抗體 |
| JP2026513101A (ja) | 2022-10-25 | 2026-04-23 | アブリンクス エン.ヴェー. | エフェクター機能が強化された糖鎖改変Fc変異ポリペプチド |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| WO2025177185A1 (en) * | 2024-02-20 | 2025-08-28 | Janssen Biotech, Inc. | Materials and methods for biologic affinity analysis |
| TW202617767A (zh) | 2024-06-14 | 2026-05-01 | 法商賽諾菲公司 | 用cd28/ox40雙特異性抗體的實體器官移植受試者的治療 |
| TW202604950A (zh) | 2024-07-23 | 2026-02-01 | 美商鳥岩生物瑟博公司 | 肥胖症之治療 |
| WO2026146204A1 (en) | 2025-01-03 | 2026-07-09 | Ablynx Nv | Compounds, constructs and compositions targeting tnf and ox40l for use in the treatment of type 1 diabetes |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3994966A (en) * | 1972-09-28 | 1976-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Chelating agents |
| US4043998A (en) * | 1974-10-09 | 1977-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid |
| US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
| US4460561A (en) * | 1980-03-03 | 1984-07-17 | Goldenberg M David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4361544A (en) * | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4444744A (en) * | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4348376A (en) * | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4460559A (en) * | 1980-03-03 | 1984-07-17 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4622420A (en) * | 1980-03-18 | 1986-11-11 | The Regents Of The University Of California | Chelating agents and method |
| US4454106A (en) * | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
| US4472509A (en) * | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| JPS5982222U (ja) * | 1982-11-26 | 1984-06-02 | 松井 三郎 | 眼鏡 |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4707352A (en) | 1984-01-30 | 1987-11-17 | Enzo Biochem, Inc. | Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group |
| US4636380A (en) | 1984-04-23 | 1987-01-13 | Wong Dennis W | Novel physiologic chemical method of labeling protein substances with the radionuclides of indium |
| US4634586A (en) * | 1984-05-21 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Reagent and method for radioimaging leukocytes |
| US4722892A (en) * | 1984-08-31 | 1988-02-02 | Meares Claude F | Monoclonal antibodies against metal chelates |
| US4824986A (en) * | 1985-04-26 | 1989-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Metal chelate protein conjugate |
| US4735210A (en) * | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) * | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4926869A (en) * | 1986-01-16 | 1990-05-22 | The General Hospital Corporation | Method for the diagnosis and treatment of inflammation |
| AU593611B2 (en) * | 1986-02-14 | 1990-02-15 | Nihon Medi-Physics Co., Ltd. | High molecular compounds having amino groups, and their utilization |
| US5246692A (en) * | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| EP0484989B1 (en) * | 1986-09-05 | 1996-04-24 | GANSOW, Otto A. | Polysubstituted diethylenetriamine chelates for forming a metal-chelate-protein conjugate |
| US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5034223A (en) * | 1986-10-09 | 1991-07-23 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
| US4921690A (en) * | 1986-12-29 | 1990-05-01 | City Of Hope | Method of enhancing the biodistribution of antibody for localization in lesions |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5217704A (en) | 1987-11-06 | 1993-06-08 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
| AU619218B2 (en) | 1987-11-06 | 1992-01-23 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
| US5130118A (en) | 1987-11-06 | 1992-07-14 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| WO1992011864A1 (en) * | 1991-01-11 | 1992-07-23 | Cryopharm Corporation | Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material |
| ATE134999T1 (de) * | 1988-05-25 | 1996-03-15 | Us Commerce | Makrocyclische chelate und verwendungsverfahren |
| US4923985A (en) * | 1988-05-25 | 1990-05-08 | The United States Of America As Represented By The Department Of Health & Human Services | Process for synthesizing macrocyclic chelates |
| US5059518A (en) * | 1988-10-20 | 1991-10-22 | Coulter Corporation | Stabilized lyophilized mammalian cells and method of making same |
| CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| US5376356A (en) * | 1989-03-14 | 1994-12-27 | Neorx Corporation | Imaging tissue sites of inflammation |
| US5162115A (en) * | 1989-05-09 | 1992-11-10 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
| US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
| US5124471A (en) * | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| US5219556A (en) * | 1990-07-09 | 1993-06-15 | Mallinckrodt Medical, Inc. | Stabilized therapeutic radiopharmaceutical complexes |
| US5009069A (en) * | 1990-08-24 | 1991-04-23 | Molini Alberto E | Method of recovering energy from ocean water |
| GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| CA2095141A1 (en) | 1990-11-05 | 1992-05-06 | Ingegerd Hellstrom | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents |
| US5208008A (en) * | 1990-11-14 | 1993-05-04 | University Of Pittsburgh | Regioselective chemical modification of monoclonal antibodies |
| US5403573A (en) * | 1992-04-23 | 1995-04-04 | The Curators Of The University Of Missouri | Radiolabeled protein composition and method for radiation synovectomy |
| US5541287A (en) | 1992-06-09 | 1996-07-30 | Neorx Corporation | Pretargeting methods and compounds |
| US5716596A (en) | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
| US5620675A (en) | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ATE139900T1 (de) * | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5650134A (en) | 1993-01-12 | 1997-07-22 | Novartis Ag (Formerly Sandoz Ltd.) | Peptides |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| IL113610A0 (en) * | 1994-06-03 | 1995-08-31 | Immunomedics Inc | A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same |
| US5686578A (en) | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US5728369A (en) | 1994-10-05 | 1998-03-17 | Immunomedics, Inc. | Radioactive phosphorus labeling of proteins for targeted radiotherapy |
| US5942210A (en) | 1994-11-15 | 1999-08-24 | Cytogen Corporation | Methods for lyoprotecting a macromolecule using tricine |
| US5830431A (en) | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| US20020102208A1 (en) * | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
-
1999
- 1999-03-01 US US09/259,337 patent/US20020102208A1/en not_active Abandoned
-
2000
- 2000-02-28 MY MYPI20000754A patent/MY138674A/en unknown
- 2000-02-29 PT PT91585141T patent/PT2112512E/pt unknown
- 2000-02-29 NZ NZ513788A patent/NZ513788A/xx not_active IP Right Cessation
- 2000-02-29 HR HR20010714A patent/HRP20010714B1/xx not_active IP Right Cessation
- 2000-02-29 WO PCT/US2000/005061 patent/WO2000052473A2/en not_active Ceased
- 2000-02-29 DK DK09158514.1T patent/DK2112512T3/en active
- 2000-02-29 CA CA2742153A patent/CA2742153C/en not_active Expired - Lifetime
- 2000-02-29 CZ CZ2010-746A patent/CZ306959B6/cs not_active IP Right Cessation
- 2000-02-29 ES ES00913645T patent/ES2328100T3/es not_active Expired - Lifetime
- 2000-02-29 PL PL352531A patent/PL205780B1/pl unknown
- 2000-02-29 CZ CZ20013126A patent/CZ303262B6/cs not_active IP Right Cessation
- 2000-02-29 RU RU2001126400/15A patent/RU2251110C2/ru active
- 2000-02-29 BR BRPI0017596A patent/BRPI0017596B8/pt not_active IP Right Cessation
- 2000-02-29 CA CA2362119A patent/CA2362119C/en not_active Expired - Lifetime
- 2000-02-29 SK SK91-2010A patent/SK288096B6/sk not_active IP Right Cessation
- 2000-02-29 HU HU1300275A patent/HU230516B1/hu unknown
- 2000-02-29 ME MEP-2009-21A patent/ME00782B/me unknown
- 2000-02-29 EP EP09158514.1A patent/EP2112512B1/en not_active Expired - Lifetime
- 2000-02-29 NZ NZ530868A patent/NZ530868A/en not_active IP Right Cessation
- 2000-02-29 UA UA2001096636A patent/UA78484C2/uk unknown
- 2000-02-29 SK SK1216-2001A patent/SK287745B6/sk not_active IP Right Cessation
- 2000-02-29 SI SI200031036T patent/SI1192463T1/sl unknown
- 2000-02-29 AT AT00913645T patent/ATE433108T1/de active
- 2000-02-29 SI SI200031085T patent/SI2112512T1/sl unknown
- 2000-02-29 ES ES09158514.1T patent/ES2526723T3/es not_active Expired - Lifetime
- 2000-02-29 CN CNB008057397A patent/CN1235639C/zh not_active Expired - Lifetime
- 2000-02-29 RS YU61601A patent/RS51778B/sr unknown
- 2000-02-29 DK DK00913645T patent/DK1192463T3/da active
- 2000-02-29 AU AU35052/00A patent/AU776747B2/en not_active Expired
- 2000-02-29 EE EEP200100465A patent/EE05650B1/xx unknown
- 2000-02-29 MX MXPA01008837A patent/MXPA01008837A/es active IP Right Grant
- 2000-02-29 BR BRPI0008719 patent/BRPI0008719B8/pt not_active IP Right Cessation
- 2000-02-29 HU HU0202522A patent/HU229627B1/hu unknown
- 2000-02-29 IL IL14510900A patent/IL145109A0/xx not_active IP Right Cessation
- 2000-02-29 PT PT00913645T patent/PT1192463E/pt unknown
- 2000-02-29 KR KR1020017011093A patent/KR100729247B1/ko not_active Expired - Lifetime
- 2000-02-29 HK HK02107258.0A patent/HK1045730B/zh not_active IP Right Cessation
- 2000-02-29 JP JP2000602634A patent/JP4704570B2/ja not_active Expired - Lifetime
- 2000-02-29 DE DE60042326T patent/DE60042326D1/de not_active Expired - Lifetime
- 2000-02-29 EP EP00913645A patent/EP1192463B1/en not_active Expired - Lifetime
- 2000-03-01 TW TW089103582A patent/TWI294969B/zh not_active IP Right Cessation
-
2001
- 2001-08-22 ZA ZA200106943A patent/ZA200106943B/xx unknown
- 2001-08-31 NO NO20014245A patent/NO329142B1/no not_active IP Right Cessation
- 2001-09-27 BG BG105957A patent/BG65690B1/bg unknown
-
2005
- 2005-01-12 US US11/033,439 patent/US7608241B2/en not_active Expired - Fee Related
-
2009
- 2009-09-01 CY CY20091100912T patent/CY1109335T1/el unknown
-
2010
- 2010-05-18 NO NO20100717A patent/NO330705B1/no not_active IP Right Cessation
-
2015
- 2015-02-16 CY CY20151100160T patent/CY1116265T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0008719A (pt) | método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo | |
| BRPI9912227B8 (pt) | método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método. | |
| BRPI0816117B8 (pt) | anticorpo monoclonal isolado ou fragmento do mesmo, composiçãofarmacêutica, kit para tratamento de desordens relacionadas com colesterol, e, uso de uma proteína de ligação de antígeno ou de um anticorpo monoclonal ou fragmento do mesmo | |
| DE69403484D1 (de) | Prüfungskit | |
| Fang et al. | Antibody-directed cell internalization of targeted covalent europium tag enables in situ kinase labeling and inductively coupled plasma mass spectrometry (ICP-MS) quantification | |
| DK1214447T3 (da) | Påvisning af pyruvatkinase-isoenzymer i fæces | |
| BR0211697A (pt) | Marcador de câncer e usos deste na diagnose de câncer | |
| ES2186121T3 (es) | Mejora de los resultados de los dosificados de inmunodeteccion gracias al empleo de varios trazadores. | |
| DE60014064D1 (de) | Einetenascin-c isoform als marker für neoplasmen | |
| ES3042244T3 (en) | Fixable viability dyes and their uses | |
| Xu et al. | Comparison of Different Competitive Proteome Profiling Approaches in Target Identification of Covalent Inhibitors | |
| ES2060146T3 (es) | Metaloproteinasas colagenoliticas asociadas con metastasis. | |
| WO2003027639A3 (en) | Glucocorticoid receptor nuclear translocation domain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2015, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/02/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2330 DE 01/09/2015 QUANTO AO PRAZO DE VALIDADE. (PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/02/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO ) |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 29/02/2020 |